Maze Therapeutics debuts with $191M to go after genetic modifiers

Third Rock Ventures launched Maze Therapeutics with $191 million in committed capital and a mission to “translate genetic insights into new medicines.” The biotech aims to make sense of the proliferation of human genetic data that has emerged in recent years and understand how some genes provide protection against disease so that they can be targeted with drugs.